Bedrijfsoverzicht
Biomea Fusion, Inc. is a clinical-stage company dedicated to the discovery and development of oral covalent small molecule drugs designed to treat patients with metabolic diseases in the United States, specifically focusing on diabetes and obesity. The company operates within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized entity focused on the therapeutic potential of oral pharmacology rather than injectable therapies. According to the latest available data, the company holds a market capitalization of $135.20M and employs a workforce of 41 individuals. The absence of reported annual revenue combined with a market capitalization of $135.20M indicates that the company is in a pre-revenue or early commercialization phase, relying on its asset pipeline rather than current sales to derive its market value. This valuation structure is typical for clinical-stage biotechnology firms where the primary asset is the intellectual property and potential future commercial success of lead candidates like icovamenib.
Financiële gezondheid
The company reports a Net Income (TTM) of $-61,797,000 and an EBITDA of $-79,898,000, while revenue data is listed as N/A, indicating a lack of commercial sales to date. The gap between revenue and net income, or rather the existence of significant net losses without reported revenue, reveals a cost structure dominated by research and development expenses necessary to advance clinical trials. Free Cash Flow stands at $-42,026,876, which signifies that the company is burning cash at a substantial rate, thereby limiting its current financial flexibility and increasing reliance on external capital sources. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the standard accounting treatment for early-stage biotech companies that have not yet generated sales to calculate meaningful margins. The company holds Cash of $55.81M against total Debt of $1.59M, resulting in a Debt to Equity ratio of 5.38. Despite the high debt-to-equity figure, the balance sheet appears to be funded primarily by equity and cash reserves rather than operational leverage, as the debt level is minimal relative to cash holdings. The Current Ratio is 5.23, which indicates a strong position in short-term liquidity, suggesting the company can easily cover its current liabilities with its current assets. Return on Equity is -152.4% and Return on Assets is -73.4%, metrics that reveal the company is currently destroying shareholder value in absolute terms due to accumulated losses rather than generating returns, a common characteristic of firms in the clinical development stage before product approval.
Waarderingsbeoordeling
The Trailing P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is -1.76, implying that the market prices in significant future losses or expects earnings to remain negative in the near term. The Price to Book ratio is 4.57, indicating that the market values the company at a significant premium over its net asset value, likely driven by the perceived potential of its drug pipeline rather than current book equity. The Price to Sales ratio is N/A and the EV/EBITDA is -1.01, suggesting that traditional sales-based valuation metrics are not applicable yet, while the negative EV/EBITDA confirms the company is not generating positive operating cash flow relative to its enterprise value. The stock has traded between a 52-Week High of $3.08 and a 52-Week Low of $0.87, and without a specific current price provided in the facts, the valuation range suggests a high degree of volatility typical for small-cap biotechnology stocks. The Beta is -0.27, which is a negative value indicating an inverse correlation to the broader market, meaning the stock price tends to move in the opposite direction of the general market index during periods of volatility.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet established a baseline of commercial revenue to calculate year-over-year expansion rates. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue because the denominator for both calculations is currently zero or non-existent. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that all available cash and retained earnings are reinvested into the business to fund clinical trials and operations rather than being distributed to shareholders. The overall growth and income profile for Biomea Fusion, Inc. is characterized by a complete reliance on future commercialization success, with no current income generation or historical growth data to analyze against peer benchmarks.